問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


E-DA Hospital (在職)

Division of Thoracic Medicine

Division of Thoracic Surgery

Division of General Internal Medicine

Division of Thoracic Medicine

E-DA Hospital (在職)

Division of Thoracic Medicine

Division of General Internal Medicine

更新時間：2023-09-19

魏裕峰
  • Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

40Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

魏裕峰

List

84Cases

2020-05-01 - 2020-06-29

Phase III

A Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Trial of CS1001 as Consolidation Treatment in Subjects with Locally Advanced/Unresectable (Stage III) Non-Small Cell Lung Cancer that Hasn’t Progressed After Prior Concurrent/Sequential Chemoradiotherapy.

  • Condition/Disease

    Non-Small Cell Lung Cancer Stage III

  • Test Drug

    CS1001

Participate Sites
6Sites

Recruiting6Sites

2019-09-01 - 2019-08-06

Phase III

Regarding tislelizumab (BGB-A317) combined with chemotherapy and radiotherapy followed by tislelizumab monotherapy for use in newly diagnosed, locally advanced, unresectable stage III non-small cell lung cancer subjects for a phase 3, random assignment, double blind, Placebo controlled trial.

  • Condition/Disease

    NSCLC

  • Test Drug

    Tislelizumab

Participate Sites
8Sites

Recruiting3Sites

Terminated5Sites

2016-09-12 - 2019-12-05

Phase III

Multicenter, Double-Blind, Randomized, Parallel-Group Study to Assess the Efficacy and Safety of MYL-1402O Compared With Avastin®, in the First-line Treatment of Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

  • Condition/Disease

    NSCLC

  • Test Drug

    MYL-1402O

Participate Sites
6Sites

Terminated6Sites

2017-06-26 - 2024-05-31

Phase III

ONO-4538 Phase 3 study A Multicenter, Randomized, Double-Blind Trial in Subjects with Non-Squamous Non-Small Cell Lung Cancer

  • Condition/Disease

    NSCLC

  • Test Drug

    Nivolumab (ONO-4538)

Participate Sites
12Sites

Terminated10Sites

楊政達
Linkou Chang Gung Medical Foundation

Division of Thoracic Medicine

夏德椿
China Medical University Hospital-Taipei

未分科

2016-07-01 - 2020-06-30

Phase III

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY OF ATEZOLIZUMAB (MPDL3280A, ANTI-PD-L1 ANTIBODY) IN COMBINATION WITH CARBOPLATIN OR CISPLATIN + PEMETREXED COMPARED WITH CARBOPLATIN OR CISPLATIN + PEMETREXED IN PATIENTS WHO ARE CHEMOTHERAPY-NAIVE AND HAVE STAGE IV NON-SQUAMOUS NON-SMALL CELL LUNG CANCER

  • Condition/Disease

    NON-SMALL CELL LUNG CANCER (NSCLC)

  • Test Drug

    Atezolizumab (MPDL3280A)

Participate Sites
10Sites

Terminated9Sites

邱昭華
Taipei Veterans General Hospital

Division of Hematology & Oncology

2016-01-01 - 2018-12-26

Phase III

SB8

  • Condition/Disease

    NSCLC

  • Test Drug

    SB8

Participate Sites
7Sites

Terminated5Sites

夏德椿
China Medical University Hospital-Taipei

未分科

劉劍英
Linkou Chang Gung Medical Foundation

Division of General Internal Medicine

2016-11-01 - 2019-11-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting8Sites

2015-01-01 - 2018-12-31

Phase III

Multicentre, randomised, double-blind, Phase III trial to investigate the efficacy and safety of oral nintedanib plus docetaxel therapy compared to placebo plus docetaxel therapy in patients with stage IIIB/IV or recurrent, adenocarcinoma subtype non-small cell lung cancer after failure of first line chemotherapy

  • Condition/Disease

    stage IIIB/IV or recurrent, adenocarcinoma subtype non-small cell lung cancer

  • Test Drug

    Nintedanib

Participate Sites
6Sites

Terminated6Sites

2018-03-01 - 2019-09-30

Others

Phase 1b/2 Safety, Pharmacokinetic, and Efficacy Study of G1T38 in Combination with Osimertinib in Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer (NSCLC)

  • Condition/Disease

    Non-Small Cell Lung Cancer, NSCLC

  • Test Drug

    G1T38

Participate Sites
10Sites

Terminated9Sites

2024-08-01 - 2025-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

1 5 6 7 8 9
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB